Genetics Research
rs363224
Population Frequencies12
African
C 0.67183A 0.32817CC 0.455489CA/AC 0.432681AA 0.11183pop=23,500
African American
C 0.66953A 0.33047CC 0.451715CA/AC 0.43562AA 0.112665pop=22,740
African Others
C 0.741A 0.259CC 0.568421CA/AC 0.344737AA 0.086842pop=760
Asian
C 0.5354A 0.4646CC 0.299827CA/AC 0.471115AA 0.229058pop=6,924
East Asian
C 0.5365A 0.4635CC 0.300974CA/AC 0.47112AA 0.227905pop=5,748
European
C 0.451579A 0.548421CC 0.207232CA/AC 0.488694AA 0.304074pop=274,446
Latin American 1
C 0.54A 0.46CC 0.293333CA/AC 0.493333AA 0.213333pop=1,800
Latin American 2
C 0.4103A 0.5897CC 0.175253CA/AC 0.470007AA 0.35474pop=8,502
Other
C 0.501A 0.499CC 0.25319CA/AC 0.495635AA 0.251175pop=5,956
Other Asian
C 0.5298A 0.4702CC 0.294218CA/AC 0.471088AA 0.234694pop=1,176
South Asian
C 0.4846A 0.5154CC 0.24416CA/AC 0.480784AA 0.275057pop=5,308
Studies26
Unread Studies26 ▼
1
Tardive dyskinesia (TD) is a potentially irreversible movement disorder that emerges in a proportion of schizophrenia patients who are prescribed antipsychotic medications. These …
2
Valbenazine (marketed as Ingrezza in the US and Dysval in Japan) is a vesicular monoamine transporter 2 (VMAT2) inhibitor used in the treatment of tardive dyskinesia (TD) or …
3
Decades of pharmacogenetic research have revealed genetic biomarkers of clinical response to antipsychotics. Genetic variants in antipsychotic targets, dopamine and serotonin …
4
Tardive dyskinesia (TD) is induced by antipsychotic drugs that have dopamine-antagonising properties. It frequently causes physical and mental anguish in individuals, lowering their …
5
Tardive dyskinesia is a severe motor adverse event of antipsychotic medication, characterized by involuntary athetoid movements of the trunk, limbs, and/or orofacial areas. It affects two …
6
Parkinson’s disease (PD) is one of the common neurodegenerative diseases, which lasts several years. The incidence is varied worldwide and increases with age in both males …
7
Tardive dyskinesia (TD) is a potentially irreversible movement disorder observed following long‐term antipsychotic exposure. Its cause is unknown; however, a genetic component has …
8
Pharmacogenetics (PGx) research over the past 2 decades has produced extensive evidence for the influence of genetic factors on the efficacy and tolerability of antipsychotic treatment…
9
… of SNPs in the SLC18A2gene that encodes VMAT2 (vesicular monoamine transporter 2) may affect TD, including the rs2015586 marker (with deleterious effects) and the rs363224 …
10
Drug-induced dyskinesia is an iatrogenic undesirable side reaction from the extrapyramidal system that occurs during the administration of drugs, most often antipsychotics …
11
Введение. Лекарственно-индуцированная дискинезия - ятрогенная нежелательная побочная реакция со стороны экстрапирамидной системы, возникающая на фоне приема …
12
Numerous genetic variants have been shown to be associated with antipsychotic response and adverse effects of schizophrenia treatment. However, the clinical application of these …
13
… The low-expression AA genotype of SCL18A2 rs363224 variant appeared to be protective against TD and this variant interacted with the putative functional DRD2 variant rs6277 […
14
The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in …
15
… (SNPs) rs2015586, rs363390, rs363224, and rs14240 to be associated with tardive dyskinesia [84] . The high-expression C allele of rs363224 was associated with higher risk and …
16
Tardive dyskinesia (TD) is an involuntary movement disorder that occurs in ∼20% of patients after extended antipsychotic use. Its pathophysiology is unclear; however, familial patterns …
17
Tardive dyskinesia (TD) is a potentially irreversible and often debilitating movement disorder secondary to chronic use of dopamine receptor blocking medications. Genetic factors have …
18
… VNTR and the TD-associated SLC18A2 marker rs363224. Results: Our preliminary analysis did … between SLC6A3 VNTR and SLC18A2 rs363224 in TD occurrence or severity (p>0.05). …
19
… VNTR and the TD-associated SLC18A2 marker rs363224. Results: Our preliminary analysis did … between SLC6A3 VNTR and SLC18A2 rs363224 in TD occurrence or severity (p>0.05). …
20
… A allele: OR = 0.799, 95% CI = 0.665–0.959, P = 0.016), while rs363224 showed a lack of association, in a study involving 561 PD patients and 491 controls.[Citation70] …
21
… found the polymorphisms rs2015586, rs363390, rs363224 and rs14240 to be associated with … rs363224 marker [Citation32], in support of the dopamine hyperactivity hypothesis of TD. …
22
First- and second-generation antipsychotics are common drugs for treatment of schizophrenia (SCZ). Both classes of drugs have different receptor-binding profiles and affinities that are …
23
Episodic memory performance is the result of distinct mental processes, such as learning, memory maintenance, and emotional modulation of memory strength. Such processes can be …
24
… была показана роль полиморфизмов rs363390, rs363224, rs14240 в возник… В данном исследовании речь шла о взаимодействии полиморфизма rs363224 с функци…
25
Pharmacogenomics is the study of the effects of genetic polymorphisms on medication pharmacokinetics and pharmacodynamics. It offers advantages in predicting drug efficacy and/or …
26
… 2010), as well as the rs363224 marker, with the low-expression AA genotype appearing to be protective against TD (p = 0.005). We further found the rs363224 marker to interact with the …
Curated Studies0 ▼
These studies were determined to be useful for this variant — check "Unused Studies" further down if curious what didn't make the cut.
No curated studies yet.
Unused Studies0 ▼
No unused studies.